{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T17:17:35Z","timestamp":1788455855389,"version":"build-2803163510"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T00:00:00Z","timestamp":1747785600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Immune-mediated necrotizing myopathy (IMNM) is a rare autoimmune disease. Efgartigimod is a human IgG antibody Fc fragment, can enhance the degradation of IgG and thus may be a promising therapeutic agent for IMNM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>All three patients exhibited proximal muscle weakness and markedly increased creatinine kinase (CK) levels. Moreover, the myositis antibody profile revealed positive anti-signal recognition particle (SRP) antibodies in all of them. Muscle biopsy performed on the first patient confirmed IMNM. Eventually, all three patients were diagnosed with anti-SRP IMNM. The first patient initially received methylprednisolone via intravenous injection and then commenced efgartigimod therapy. The second and third patients were treated with a combination of methylprednisolone intravenous injection and efgartigimod. The efficacy of efgartigimod treatment was evaluated by observing the changes in CK values and the manual muscle testing (MMT) score. Safety assessments included adverse events and serious adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Following one cycle of efgartigimod treatment (administered at a dosage of 10\u202fmg\/kg, once a week for a total of 4 injections in one period) in these three patients, CK values decreased by 79.30, 95.80, and 93.62%, respectively. Their MMT score increased from 232, 156, and 169 to 242, 258, and 229, respectively. Evidently, these three patients demonstrated significant improvement in muscle strength and decrease of serum CK levels after efgartigimod treatment. No serious adverse events were observed during the efgartigimod treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Early application of efgartigimod in combination with methylprednisolone for the treatment of anti-SRP-IMNM led to a substantial decrease in CK values and effectively improved muscle strength. Consequently, Efgartigimod may prove to be an effective and safe therapeutic option for IMNM.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fneur.2025.1560483","type":"journal-article","created":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T00:10:52Z","timestamp":1747786252000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Efgartigimod combined with steroids as a fast-acting therapy for anti-SRP immune-mediated necrotizing myopathy"],"prefix":"10.3389","volume":"16","author":[{"given":"Qiqi","family":"Peng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoping","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feifei","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhangyu","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,21]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.nmd.2004.02.006","article-title":"119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10\u201312 October 2003, Naarden, the Netherlands","volume":"14","author":"Hoogendijk","year":"2004","journal-title":"Neuromuscul Disord"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.nmd.2017.09.016","article-title":"224th ENMC international workshop","volume":"28","author":"Allenbach","year":"2018","journal-title":"Neuromuscul Disord"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1097\/md.0000000000000028","article-title":"Anti-HMGCR autoantibodies in European patients with autoimmune necrotizing myopathies","volume":"93","author":"Allenbach","year":"2014","journal-title":"Medicine"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1002\/art.30344","article-title":"Correlation of anti-signal recognition particle autoantibody levels with creatine kinase activity in patients with necrotizing myopathy","volume":"63","author":"Benveniste","year":"2011","journal-title":"Arthritis Rheum"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"4087","DOI":"10.1002\/art.34673","article-title":"Antibody levels correlate with creatine kinase levels and strength in anti\u20133-hydroxy-3-methylglutaryl-coenzyme a reductase\u2013associated autoimmune myopathy","volume":"64","author":"Werner","year":"2012","journal-title":"Arthritis Rheum"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1038\/s41577-021-00543-w","article-title":"Autoantibodies in neurological disease","volume":"21","author":"Pr\u00fcss","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/s1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"5511","DOI":"10.1007\/s10072-024-07678-3","article-title":"Shi J-Q successful treatment with efgartigimod as an add-on therapy in acute attack of anti-AQP4 antibody-positive NMOSD: a case report","volume":"45","author":"Huang","year":"2024","journal-title":"Neurol Sci"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"3506","DOI":"10.1007\/s00415-024-12321-4","article-title":"Efgartigimod in the treatment of Guillain\u2013Barr\u00e9 syndrome","volume":"271","author":"Zhang","year":"2024","journal-title":"J Neurol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"5911","DOI":"10.1007\/s00415-024-12556-1","article-title":"Jiang Y-Q resolution of anti-LGI1-associated autoimmune encephalitis in a patient after treatment with efgartigimod","volume":"271","author":"Zhu","year":"2024","journal-title":"J Neurol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"e30421","DOI":"10.1016\/j.heliyon.2024.e30421","article-title":"Efgartigimod as rescue treatment in acute phase of neuromyelitis optica spectrum disorder: a case report","volume":"10","author":"Li","year":"2024","journal-title":"Heliyon"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3389\/fimmu.2024.1447182","article-title":"Treatment of refractory immune-mediated necrotizing myopathy with efgartigimod","volume":"15","author":"Yang","year":"2024","journal-title":"Front Immunol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"11781","DOI":"10.1016\/S0021-9258(17)39098-1","article-title":"Alu RNA-protein complexes formed in vitro react with a novel lupus autoantibody","volume":"260","author":"Kole","year":"1985","journal-title":"J Biol Chem"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"9507","DOI":"10.1073\/pnas.83.24.9507","article-title":"Human autoantibodies reactive with the signal-recognition particle","volume":"83","author":"Reeves","year":"1986","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1002\/art.1780330908","article-title":"Antibody to signal recognition particle in polymyositis","volume":"33","author":"Targoff","year":"1990","journal-title":"Arthritis Rheum"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"2757","DOI":"10.1002\/art.27572","article-title":"A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy","volume":"62","author":"Christopher-Stine","year":"2010","journal-title":"Arthritis Rheum"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1002\/art.30156","article-title":"Autoantibodies against 3-Hydroxy-3-Methylglutaryl-coenzyme a reductase in patients with statin-associated autoimmune myopathy","volume":"63","author":"Mammen","year":"2011","journal-title":"Arthritis Rheum"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.autrev.2009.03.005","article-title":"Use of a commercial line blot assay as a screening test for autoantibodies in inflammatory myopathies","volume":"9","author":"R\u00f6nnelid","year":"2009","journal-title":"Autoimmun Rev"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1136\/jnnp-2016-313166","article-title":"Clinical features and prognosis in anti-SRP and anti-HMGCR necrotising myopathy","volume":"87","author":"Watanabe","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1093\/brain\/aww054","article-title":"High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specific antibody","volume":"139","author":"Allenbach","year":"2016","journal-title":"Brain"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"R39","DOI":"10.1186\/ar1895","article-title":"High S human autoantibodies against the 54 kDa protein of the signal recognition particle block function at multiple stages","volume":"8","author":"R\u00f6misch","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/nature08870","article-title":"Recognition of a signal peptide by the signal recognition particle","volume":"465","author":"Janda","year":"2010","journal-title":"Nature"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"R39","DOI":"10.1186\/ar4468","article-title":"Exploring necrotizing autoimmune myopathies with a novel immunoassay for anti-3-hydroxy-3-methyl-glutaryl-CoA reductase autoantibodies","volume":"16","author":"Drouot","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1002\/ana.24902","article-title":"Pathogenic role of anti\u2013signal recognition protein and anti\u20133-Hydroxy-3-methylglutaryl-CoA reductase antibodies in necrotizing myopathies: Myofiber atrophy and impairment of muscle regeneration in necrotizing autoimmune myopathies","volume":"81","author":"Arouche-Delaperche","year":"2017","journal-title":"Ann Neurol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1212\/wnl.0000000000004923","article-title":"Necrosis in anti-SRP+ and anti-HMGCR+ myopathies","volume":"90","author":"Allenbach","year":"2018","journal-title":"Neurology"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1136\/annrheumdis-2018-213518","article-title":"In vivo pathogenicity of IgG from patients with anti-SRP or anti-HMGCR autoantibodies in immune-mediated necrotising myopathy","volume":"78","author":"Bergua","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3390\/biomedicines10082036","article-title":"Prevention of anti-HMGCR immune-mediated Necrotising myopathy by C5 complement inhibition in a humanised mouse model","volume":"10","author":"Julien","year":"2022","journal-title":"Biomedicines"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"4006","DOI":"10.1093\/rheumatology\/kead298","article-title":"Efgartigimod restores muscle function in a humanized mouse model of immune-mediated necrotizing myopathy","volume":"62","author":"Julien","year":"2023","journal-title":"Rheumatology"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1093\/rheumatology\/keac115","article-title":"British Society for Rheumatology guideline on management of paediatric, adolescent and adult patients with idiopathic inflammatory myopathy","volume":"61","author":"Oldroyd","year":"2022","journal-title":"Rheumatology"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"e67","DOI":"10.1016\/s2665-9913(23)00003-6","article-title":"Zilucoplan in immune-mediated necrotising myopathy: a phase 2, randomised, double-blind, placebo-controlled, multicentre trial","volume":"5","author":"Mammen","year":"2023","journal-title":"Lancet Rheumatol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"4372","DOI":"10.1172\/jci97911","article-title":"Neonatal fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans","volume":"128","author":"Ulrichts","year":"2018","journal-title":"J Clin Invest"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1007\/s00415-022-11517-w","article-title":"Efgartigimod improved health-related quality of life in generalized myasthenia gravis: results from a randomized, double-blind, placebo-controlled, phase 3 study (ADAPT)","volume":"270","author":"Sacca","year":"2023","journal-title":"J Neurol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.neurot.2024.e00378","article-title":"Subcutaneous efgartigimod PH20 in generalized myasthenia gravis: a phase 3 randomized non-inferiority study (ADAPT-SC) and interim analyses of a long-term open-label extension study (ADAPT-SC plus)","volume":"21","author":"Howard","year":"2024","journal-title":"Neurotherapeutics"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/S1474-4422(24)00309-0","article-title":"Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trial","volume":"23","author":"Allen","year":"2024","journal-title":"Lancet Neurol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1016\/s0140-6736(23)01460-5","article-title":"Efficacy and safety of the neonatal fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"402","author":"Broome","year":"2023","journal-title":"Lancet"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"1444288","DOI":"10.3389\/fimmu.2024.1444288","article-title":"Case report: rapid symptom relief in autoimmune encephalitis with efgartigimod: a three-patient case series","volume":"15","author":"Zhang","year":"2024","journal-title":"Front Immunol"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2025.1560483\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T00:10:53Z","timestamp":1747786253000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2025.1560483\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,21]]},"references-count":36,"alternative-id":["10.3389\/fneur.2025.1560483"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2025.1560483","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,21]]},"article-number":"1560483"}}